Life Sciences Archive » May, 2015

Life Sciences - May, 2015

311 articles

• Namenda Product-Hopping Ruling Opens Door To More Claims
• Namenda Isn't End Of NY AG's Pharma Work: Antitrust Chief
• 21 Investigations Added To HHS Oversight Agenda
• Ex-Merck Director's Pregnancy Bias Suit Heads To Jury
• Brand Battles: Bayer, Lego, Coca-Cola
• 4 IPOs Eye $552M To Start June After Brief Slowdown
• FDA Asked To Add HIV Warning To Birth Control Label
• New Wash. Law Invites Tribes Mulling Marijuana Biz
• 4 In-House Preferences For Better Outside Counsel
• FDA Botched Amarin's Vascepa Exclusivity, Judge Rules
• FTC Sues To Block $1.9B Steris-Synergy Merger
• Pa. Judge Urged To Keep 1st Pelvic Mesh Cases In Philly
• Shining A Light On Conn.'s Version Of The Sunshine Act
• Bio-Rad's Ex-GC Sues Over Firing Amid Bribery Investigation
• Pay-For-Delay Questions Linger After $1.2B Cephalon Deal
• 2nd Circ. Says Coercion Key To Namenda Injunction Ruling
• FTC's $1.2B Win Shows Pay-For-Delay Deals On Thin Ice
• No More Delays, Plaintiffs In Shire Pay-For-Delay Suit Told
• Daiichi Sankyo Looks To Fuse NJ Benicar Suits
• Paying The Price For Pay-For-Delay: Cephalon's 7-Year Saga
• Blue Cross Sued For Denying Gilead Hep C Drug Coverage
• Nautilus Asks Full Fed. Circ. To Review Indefiniteness Case
• Allergan Shakes Shareholders' Off-Label Botox Case
• Ruling Clears Way For Medical Cannabis In Florida
• FTC Health Care Chief: $1.2B Cephalon Deal A Strong Warning
• Analyzing Data Trends To Shape Complex Litigation Strategy
• Medtronic Wins Fees In Long-Running Mirowski Patent Case
• Boston Scientific Hit With Record $100M Verdict In Mesh Case
• Cancer Biotech MultiVir Pulls Plug On IPO Plans
• Internal Microbe Ecology Biotech Seres Eyes $100M IPO
• 7th Circ. Weighs Copyright Suit Over Amylin Drug Promos
• IP Firm Dodges Sanctions In Medical Device Co.'s Suit
• PE Firm Cinven To Buy France's Labco In $1.3B Deal
• Persuasive Experts At Trial: 3 Times A Charm
• Cephalon To Pay $1.2B To End FTC Pay-For-Delay Suit
• Acorda Hits Back At Hedge Fund Manager In PTAB Challenge
• FDA Beats Otsuka Suit Over Abilify Generics
• AbbVie Buys Back $5B Stock As Pharmacyclics Deal Sealed
• 2 VC-Backed Medical Device Cos. Aim For $147M In IPOs
• Pfizer Says Zoloft Birth Defect Suit Can't Wait For Science
• NJ Justices Won't Hear Dispute Over Generic Drug Settlement
• Ex-Bryan Cave Client Can't Escape $1.5M Fee Row
• And Now A Word From The Panel: The MDL Lexicon
• Philly Risperdal Trial Settles On Day Of Opening Arguments
• Allergan Can't Duck Eye Doctors' FCA Kickbacks Suit
• FDA Biosimilar Policy: More Questions, More Answers
• A New Compliance Challenge For Cos. Doing Business In UK
• NJ Appeals Court Boots Pharma Ad Exec's GoDaddy Suit
• 5 FCA Takeaways From High Court's KBR Ruling
• 9th Circ. Denies En Banc Rehearing For Amgen ERISA Suit
• High Court Won't Hear PhRMA's Appeal Of Drug Cleanup Law
• Causation Key For J&J In Philly Risperdal Fight
• Medicare Fraudster Gets 7 Years For $3.3M Scam
• Merck Offers EU Antitrust Fixes On $17B Sigma-Aldrich Buy
• Law360 Looking For IP Experts For New Series
• 2nd Circ. Asks How Expert Report Could Derail Pfizer Action
• Mass. Suit Over Zogenix Painkiller Restrictions Paused
• Bayer, Merck Hit In Pa. Court Over Avelox Nerve Damage
• Bolder Cures Act Could Ease Limits On Drug Cost Claims
• Amarin Seeks Injunction Blocking FDA's Off-Label Muzzle
• Pfizer MDL Plaintiffs Blast Bernstein Liebhard's Fee Bid
• Insurance Risks Surrounding Legal Cannabis
• 5 Insights From CBRE General Counsel Laurence Midler
• Mylan Says Kirkland 'Thumbs Its Nose' At Client Loyalty
• Philly Zoloft Trial Can Shape Expert Testimony In MDL
• Hagens Berman In Hot Seat Over Dropped GSK Suits
• 6th Circ. Upholds GE's Win In Omniscan Suit
• Natrol Gets Nod For Ch. 11 Plan Over IRS Opposition
• Hedge Fund Hits 'Ridiculous' Horizon Patent With AIA Review
• WilmerHale Guides Custom Joint Co. On $173M IPO Plan
• Medtronic Fights IRS Over Sealed Docs In $561M Tax Row
• Taxation With Representation: Sullivan, Ropes & Gray
• Actavis Faces Patent Suit Over Generic Opioid
• 2nd Circ. Says Actavis Can't Pull Old Namenda
• Calif. Justices Urged To Reconsider Pay-For-Delay Ruling
• FDA Adjusts Blood Donation Rules To Test For More Diseases
• AstraZeneca Loses Bid To Nix $42M Award In UK Generic Row
• Kirkland Says Work For Mylan Units Can't Trigger Conflict
• USPTO Joins Bayer's 'Flanax' Foreign Trademark Case
• Watson, Not Par, Infringed Novartis Dementia Patch: Fed. Circ.
• SAC Tipster Dropped From Investor Class Action
• 4 Issues To Watch As 21st Century Cures Act Advances
• Judge OKs Unlimited Damages For Tylenol Liver Bellwether
• Plaintiffs Gain Some Docs In Adderall Suit, May Get Others
• Novartis Catches Flak For Clawback Bid In FCA Kickback Row
• A Route To Directors' Early Exit From Merger Litigation
• Astellas Gets OK For $98M Deal In Prograf Antitrust MDL
• LifeCell Wins Duty-To-Warn Ruling In NJ AlloDerm Litigation
• Grassley Says Patent Troll Bill Will Tackle AIA 'Abuse'
• Sullivan & Cromwell Guides CVS In $12.7B Deal For Omnicare
• House OKs R&D Tax Credit, $33B In Research Funds
• Cooley Guides Adamas Pharma On $150M Follow-On
• Hernia Mesh Maker Wins Injunction In Trade Secrets Fight
• Knobbe Atty's Misconduct Doesn't Kill $467M Masimo Verdict, Judge Says
• VC Firm Raises $215M For University-Research Startup Fund
• Debt, Equity Markets Heat Up As Pharma M&A Soars
• FTC's Abbvie Loss Doesn't Apply To Actos Case, Court Told
• Janssen Scores FDA Approval For New Schizophrenia Drug
• Congress Could Be Coming For Dietary Supplements Soon
• Hagens Berman Objections To GSK Settlement Probe Rebuffed
• Pfizer Urges Zoloft MDL Judge To Block Plaintiffs' New Expert
• 2015 Law360 Minority Report
• The 50 Best Firms For Minority Partners
• Diversity Gap A Growing Threat To BigLaw Bottom Lines
• The 100 Best Law Firms For Minority Attorneys
• NuVasive Can't Nix Jury's $2.6M Fraud Verdict On Appeal
• Drunken Drivers Urge Justices To Hear Faulty BAC Test Suit
• J&J Will Pay $7.8M To Exit Ark. Risperdal Marketing Suit
• NECC's Ch. 11 Plan With $200M Meningitis Payouts Approved
• Robbins Geller $94M Fee In Pfizer Suit Too High, Judge Told
• Shire Investors Say AbbVie Can't Ax Suit Over Failed Inversion
• ITC To Investigate Hemophilia Drug Imports
• Pa. Firms See Green, But Want Ethics Rules For Medical Pot
• Lobbying The EU: New Requirements For A 'Voluntary' Regime
• New Medicaid Bill Targets Soaring Generic-Drug Prices
• Phony Docs Torpedo $25M Verdict In Trade Secret Row
• Cardiovascular Biotech Celyad Targets $115M In US IPO
• Ex-Sanofi Worker Files Class Action Over Stock Drop
• Man Accused Of Smear Campaign To Short Stock Skips Court
• Last Pa. Reglan Preemption Challenge Denied By High Court
• High Court Won't Bite On Fixodent MDL Evidence Claim
• Olympus Sued In Pa. Over FDA-Flagged Uterine Surgery Tool
• Sweet Home No More, Innovator Liability Leaves Alabama
• Consider 5 Things Before Choosing An E-Discovery Provider
• Skadden Guides Endo In $8B Deal For Generics Co. Par Pharma
• Citibank Appeals Denial Of Standing In Natrol Ch. 11
• Stryker Gets $9M In TIG Insurance Knee Replacement Deal
• 23andMe Gets Some Insurer Claims Paused In DNA Test Row
• Sensa Hits Doc With Contract Suit After $26M FTC Accord
• Another NJ Doc Sentenced In $100M Blood Lab Bribe Scheme
• Full 10th Circ. Won't Rehear Medtronic Infuse Injury Suit
• Pepper Hamilton Adds Ex-Norton Rose Fulbright M&A Pro
• Mylan To Appeal Dismissal Of Doryx Product-Hopping Suit
• Covidien Accused Of Firing Salesman For Reporting Kickbacks
• Circassia Plunks Down $376M For 2 Asthma Treatment Cos.
• Darvocet Warning Suits Should Go Back To Calif., Judge Says
• FDA Warns Of Diabetes Drugs From AstraZeneca, Janssen
• GSK Files New Suit Against Teva Over Generic Wellbutrin
• EQT's $621M IPO Nabs Spotlight Amid Rough Week For Debuts
• Agriculture Biotech Arcadia Raises $61.5M In Slashed IPO
• Genomic Profiling Is Double-Edged Sword In Drug Litigation
• Del. High Court Opens Exit Door For Directors In Buyout Suits
• Class Actions Are Biggest Worry For US GCs
• CVS Ducks Contract Case After Pharmacy Drops Claims
• 10th Circ. Calls Timeout On Utah Contact Lens Pricing Law
• GCs Rightly Fear The Regulators
• Five Prime Targets $200M In Follow-On Offering
• FedEx Can't Duck Criminal Case Over Drug Shipments
• Agriculture Biotech Co. Arcadia Trims IPO Expectations
• 3 VC-Backed Biotechs Join Flurry Of Anticipated IPOs
• Galapagos Scores $275M As IPO Beats Sweetened Terms
• As TPP Deal Looms, Pols Double-Dig In On Drug Patents
• Parsing Pros And Cons Of FDA's Expedited Access Pathway
• Court-Appointed Experts — A Powerful But Rarely Used Tool
• Merck Nabs Partial Win In Vioxx Securities Fraud Row
• Takeda Says FTC's AbbVie Loss Backs Actos Dismissal Bid
• Glaukos Eyes IPO As Life Sciences Hit Rough Patch
• Masimo Won't Face Charges Over Blood-Testing Devices
• FDA Shows How Patient Opinions Support Device Approvals
• Fed. Circ. Vacates Elan's Win In Classen Patent Suit
• Sandoz Wants Amgen To Post $180M Bond For Losses
• Bankruptcy Judge Greenlights SIGA Insider Trading Probe
• GSK Urges Dismissal Of Hagens Berman Thalidomide Suits
• House Panel Rolls Out Latest '21st Century Cures' Bill
• Siemens To Pay $6M To End Gov't Overcharging Investigation
• Boston Scientific Finances Endo Deal With $1.85B Debt Sale
• Nestle Health Science Says Competitor's Generic Is Fake
• E-Cigarette Class Actions Could Be On Fire Someday
• Takeaways From FTC Settlement With Cardinal Health
• Shearman & Sterling Advises Pall In $13.8B Sale To Danaher
• Fla. Judge Nixes Bond For Convicted Stock Scheme Atty
• Kirkland's Past With Mylan Rivals May Boost Conflict Defense
• Hagens Berman Fights Thalidomide Plaintiff 'Interrogations'
• FDA Unveils New Biosimilars Q&A
• Baxter Expands Cancer Therapies With $900M Oncaspar Buy
• 4 Issues To Watch In Amarin's Off-Label Marketing Suit
• Biotech Firm Galapagos NV Pegs Rosier $250M IPO Goal
• Ranbaxy Accused Of Filing Deceptive Drug Applications
• Hospira, Par Pharma Settle Epinephrine False Ad Suit
• Giant Eagle Hits AbbVie With AndroGel Pay-For-Delay Suit
• J&J Cleared Of RICO Charges Over Risperdal Side Effects
• Allergan Consumers Want Class Status In Skin Cream Suit
• FTC Hits Weight Loss Supplement Maker With False Ad Suit
• Key Considerations For Investing In Marijuana Companies
• Sheppard Mullin Boosts IP Group With Ex-Kilpatrick Patent Pro
• Pfizer, Wyeth Sued After Advil 'Melts' Girl's Skin Off
• FDA Biosimilar Policy: 3 Documents, 1 Key Theme
• Yanking Namenda IR Would Cost Medicare $6B, 2nd Circ. Told
• Contact Lens Makers Can't Delay Utah Pricing Agreement Law
• Whistleblowers Decry Allergan's FCA Immunity Bid
• Novartis Prevails In Liability Suit Over Aredia
• Cherokee Suit Against Takeda Transferred To Actos MDL
• AbbVie Not Allowed To See FTC Docs In Pay-For-Delay Suit
• Accutane Ruling Blocking Expert Testimony Kills 2K Suits
• Endo Slams Walgreens' Lidoderm Pay-For-Delay Suit
• Endo Settles 100 Vaginal Mesh Suits
• J&J Plans Appeal Of $3M Award In Topamax Birth Defects Suit
• Wash. Gov. Signs Law To Allow Tribal-State Marijuana Pacts
• Teva, Others Dodge Chicago's Suit Over Painkiller Marketing
• Ethicon Surgical Stapler Suit Belongs In Germany, Judge Says
• Teva's Effect On Review Of PTAB Claim Construction Rulings
• Bankrupt Siga Blasts Creditors' Investigation Bid
• Amarin Says Off-Label Marketing Rules Flout 1st Amendment
• Calif. High Court Fleshes Out Pay-For-Delay Test In Cipro
• Natrol Judge Delays Ch. 11 Plan Confirmation
• Tallgrass' $1.2B IPO Nabs Spotlight As 4 Biotechs Postpone
• Vitamin Shoppe Pulls Untested, Amphetaminelike Ingredient
• Calif. High Court's Cipro Ruling Is A Relief For Pharma Cos.
• Week's 9 IPOs Set To Test Investors' Thinning Risk Appetite
• 3rd Circ. Says ERISA Allows 'Catalyst Theory' Fees
• Heart Device Co. Wants Opposing Counsel DQ'd In IP Dispute
• Pfizer MDL's $91M Atty Fees Misallocated, Firm Says
• 1st Circ. Strengthens Preemption For Brand-Name Drug Cos.
• Grunenthal, Sanofi Must Wait For Thalidomide Suit To Play Out
• Bernstein Litowitz To Co-Lead Allergan Investor Suit
• Liberty Medical Gets Nod For Ch. 11 Disclosure Statement
• Collegium Prices $70M IPO As Another Biotech Postpones
• Fed. Circ. Rules Only It Can Hear AIA Interference Appeals
• Rite Aid Joins Pay-For-Delay MDL Over Generic Niaspan
• Fed. Circ. Affirms Invalidity Of AstraZeneca Inhaler Patent
• Give Brand Biologics, Biosimilars Same Naming Rules: Sandoz
• Foreign Medical Cos. Cop To $33M Drug Smuggling Scheme
• 5 Must-Know Facts For Companies Blowing The FCA Whistle
• BASF Sells 3 Drug Ingredients Plants To Siegfried For $304M
• Forest City Lobs $731M Offering To Back MIT Portfolio Buy
• FDA Recalls Maquet Heart Device Over Death, Injury Reports
• FDA Mostly Improving Generic-Drug Inspections, Report Finds
• Sandoz Says Allergan Glaucoma Patents Adds 'Nothing New'
• J&J, NYU Med School To Create 'Compassionate Use' Panel
• Calif. High Court OKs Pay-For-Delay Challenges
• Clearing The Smoke Surrounding Policy On Marijuana Apps
• Feds Intervene Against Novartis After Co-Defendant Settles
• Patient Says Intuitive Surgical's Robot Causes Severe Injuries
• 3-D Printing Of Medical Devices Has Many Dimensions
• Ala. Generics Injury Ruling May Still Sway Other States
• Robbins Geller Seeks $94M Fees In $400M Pfizer Class Deal
• Del. High Court Asked To Let Directors Out Of Buyout Suits
• Judge Trims FTC's Pay-For-Delay Suit Against AbbVie
• Fed. Circ. OKs Hikma Gout Drug Sales In Takeda IP Case
• Two Doctors Sentenced In Medical Lab Bribery Scheme
• Dead Soldier's Parents Say GNC Can't Slip 'Jack3d' Suit
• Teva Says Antitrust OK Just Months Away For $43B Mylan Deal
• Health Care Recruiter Sues Ex-Employee For Stealing Secrets
• Endoscope Maker EndoChoice Plans $115M IPO
• Fish Grows IP Practice With Hughes Hubbard Pharma Pro
• Cooley Leads HTG In Week's 2nd Diagnostics IPO
• Prosensa Beats IPO Investors' Suit Over Failed Drug
• Amgen Wins Delay Of Sandoz Biosimilar At Fed. Circ.
• Cancer Biotech Adaptimmune Files $191M IPO
• Pillsbury Adds Ex-Baker Botts Tech Partner To Austin Office
• Alexion To Buy Synageva For $8.4B In Latest Big Pharma Deal
• Scrapping Drug Price Controls, China Vows Market Vigilance
• Corporate Perspectives On Cybersecurity: A Survey Of Execs
• Teva And The Dictionary: A Status On The Standard Of Review
• Wachtell Guides AbbVie In $16.7B Bond Offering
• Boston Scientific Didn't Test Pelvic Mesh, Jury Told
• Veteran Pharma GC Says Startup Gig Flexes Legal Muscles
• Mylan's Kirkland Suit May Hold Clues For Conflict Waivers
• Biotronik Wants Insurers' $28M Pacemaker Verdict Suit Axed
• 11th Circ. Flips Contempt Order Against Hi-Tech Execs
• Pa. Federal Court Picks Trial Suits In Zoloft Birth Defect MDL
• Allergan Heirs Accuse McDermott Of Elder Abuse, Malpractice
• 500 Groups Urge Congress To Nix ACA Cost-Control Board
• Citibank Denied Bid To Delay Natrol Ch. 11 Plan Confirmation
• Dozens Of State Law Claims Sliced From Lidoderm MDL
• Allergan Counterclaims Stand In $600M Botox Royalty Row
• Honigman Boosts Mich. Practice With 2 PE, Securities Pros
• Drug Return Co. Worker Pleads Guilty In $116M Diversion Plot
• Bayer Can't Ship Reinstated Whistleblower 500 Miles Away
• Migraine Drug Developer CoLucid Slashes IPO Target
• Olavi Dunne Adds 2 Ex-Russ August Attys To Head LA Office
• Takeda's $2.4B Actos Deal Ends 5th Circ. Appeal
• Cubist Tells Fed. Circ. MRSA Drug Patents Are Valid
• An In-Depth Look At The Personal Care Products Safety Act
• B&L Sues To Stop Production Of Generic Eyedrops
• WilmerHale Leads Epizyme In $250M Follow-On Offering Plans
• DaVita To Pay Record $495M To Settle Kidney Drug FCA Suit
• Kirkland Takes Mylan's Teva Conflict Suit To Federal Court
• Heart Risk Claims Still Dog Pfizer Testosterone Drug
• Bayer Wants Out Of One-A-Day Labeling Class Action
• Lincare Says 'Arcane' FCA Suit Based on Unknowable Regs
• Justices Won't Review Invalidation Of Bristol-Myers Patent
• FDA Tries To Clear Path To Pediatric Device Approvals
• 1 Law Firm Dominates April IPO Activity
• AstraZeneca Urges Fed. Circ. To Find Asthma Inhaler IP Valid
• FTC Gets Restraining Order Against 'Bogus' Diet Pills Co.
• J&J, Ethicon Lose Bid To Toss $5.7M Pelvic Mesh Verdict
• Teva's FDA Testing Violates Lovenox Patent, Fed. Circ. Told
• Lupin Smacked With IP Suit Over Generic Paxil
• IRS Balks At Natrol Liquidation Plan Over 11th-Hour Deal
• Patterson Cos. To Pay $1B For Animal Health International
• Mylan Sues Kirkland & Ellis Over Teva Takeover Bid
• Accredo To Pay $60M In Novartis Exjade Kickback Suit
• Ala. Undoes Brand Drug Liability For Generic Injury
• IPO Activity Set To Spring Back As 14 Cos. Target $2B
• Sens. Ask FTC To Probe Supplements With Untested Ingredient
• Tygacil Injury Suit Against Pfizer Trimmed
• Brand Battles: Sears, Red Bull, Novartis
• Feds Attack Natrol's Ch. 11 Plan For Favoring Equity
• Thermo Fisher Tells Fed. Circ. Not To Mull $61M Verdict Toss
• Texas High Court Won't Hear Fen-Phen Referral Fee Fight
• Eli Lilly Rips Expert For 'Unreliable' Cymbalta Testimony
• Week's 4 IPOs Draw $795M As Market Revs Up For May Surge
• New Health Frauds Abound In Big Calif. District, DOJ Attys Say
• Apotex Seeks 1st-Ever High Court Inequitable Conduct Review
• Antitrust Suit Over Allergan Pink-Eye Meds Heads For Trial
• Omnicare Wants To Boot One Relator From FCA Kickback Suit
• USPTO Tells 4th Circ. Bayer Has Standing In 'Flanax' TM Row
• Stryker Resolves Unintended Bone Growth Suit
• Investor Wants Gordon Rees Booted From Securities Suit
• The Language Of The DQSA Contradicts Congressional Intent